$RNXT RenovoRx today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah. The abstract will highlight the Company’s lead product candidate, RenovoGem™, and proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC), a difficult-to-access, solid tumor cancer. For details: https://bit.ly/3NAWc74

#SIR24SLC #PancreaticCancer #LocallyAdvancedPancreaticCancer #LAPC https://www.linkedin.com/posts/renovorx_sir24...er_desktop